OSAKA, Japan, October, 21, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi presented results from non-clinical studies and from the Japanese Phase 1 clinical trial of S-217622, an oral antiviral drug for …